绝经后晚期乳腺癌优化治疗策略.pptVIP

Optimal treatment of Er positive/HER-2 negative postmenopausal advanced breast cancer and future perspectives Angelo Di Leo Sandro pitiglianiMedical Oncology Department Hospital of Pra Istituto Toscano Tumori, Prato, Italy *当★ Fondazione Sandro Pitigiani Previous data suggesting an interaction between fulvestrant dose and activity 0018: Post-treatment Mean ER H-scores 20/21: Prospective Combined Analysis 2.ing/ml Previous data from phase li randomized studies testing Fulvestrant 500 mg: the neWest trial Postmenopausal women with ER+ breast cancer T2. 3. 4b,No-3, Mo); tumor 22 CI Baseline Tu